KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma (Q33893010)

29 July 2017

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma (English)

1 reference

low-grade serous carcinoma

29 July 2017

1 reference

0 references

Kwong-Kwok Wong

9

0 references

Anais Malpica

6

object named as

Anais Malpica

1 reference

29 July 2017

8

David M Gershenson

1 reference

29 July 2017

Yvonne T Tsang

1

1 reference

29 July 2017

Michael T Deavers

2

1 reference

29 July 2017

Charlotte C Sun

3

1 reference

29 July 2017

Suet-Yan Kwan

4

1 reference

29 July 2017

Eric Kuo

5

1 reference

29 July 2017

Samuel C Mok

7

1 reference

29 July 2017

1 December 2013

1 reference

29 July 2017

1 reference

29 July 2017

231

1 reference

29 July 2017

4

1 reference

29 July 2017

449-456

1 reference

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Fallopian tube precursors of ovarian low- and high-grade serous neoplasms

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Ovarian low-grade serous carcinoma: a comprehensive update

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Low-grade serous carcinomas of the ovary contain very few point mutations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Predicting the functional impact of protein mutations: application to cancer genomics

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Data mining using the Catalogue of Somatic Mutations in Cancer BioMart

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Risk factors for recurrence of ovarian borderline tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

The pathology of and controversial aspects of ovarian borderline tumours

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

SNP genotyping using the Sequenom MassARRAY iPLEX platform

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Borderline ovarian tumors: current concepts for prognostic factors and clinical management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Contemporary treatment of borderline ovarian tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPATH.4252

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPATH.4252

Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPATH.4252

Detection of K-ras mutations in lung carcinomas: relationship to prognosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095747

Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy

29 October 2018

1 reference

12 December 2020

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

1 reference

12 December 2020

The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent

1 reference

12 December 2020

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants

1 reference

12 December 2020

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma

1 reference

12 December 2020

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

12 December 2020

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential

1 reference

12 December 2020

Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases

1 reference

12 December 2020

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

1 reference

12 December 2020

Identifiers

DOI

10.1002/PATH.4252

1 reference

29 July 2017

1 reference

29 July 2017

1 reference